How Will The Granulomatosis With Polyangiitis Treatment Market Reach $3.44 Billion By 2029 Amid Global Shifts?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Current Size And Growth Outlook For The Granulomatosis With Polyangiitis Treatment Market?
In the past few years, the market size for granulomatosis with polyangiitis treatment has shown robust growth. An increase from $2.36 billion in 2024 to $2.55 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.9%, is expected. This growth during the historical period is due to the escalating need for the drugs, augmented clinical trials, heightened demand for potent treatment, an increased focus on personalized medicine, and a rise in diagnosis rates for the disorder.
In the upcoming years, the market for granulomatosis with polyangiitis treatment is predicted to experience substantial growth. It’s anticipated to expand to $3.44 billion by 2029, reflecting a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this upswing during the forecast period include the growing incidences of autoimmune conditions, a surge in granulomatosis cases, increased instances of polyangiitis, and a heightened prevalence of immunological disorders. Key market trends over the forecasted period are expected to be innovations in the creation of drugs, breakthroughs in the healthcare field, advancements in diagnosis methods, new treatment options, and the emergence of biologics and biosimilars.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21196&type=smp
What Growth-Enabling Forces Are Impacting The Granulomatosis With Polyangiitis Treatment Market?
The granulomatosis with polyangiitis treatment market is projected to expand due to the rising instances of autoimmune diseases. These illnesses arise when the body’s immunity system inadvertently targets its own healthy cells and tissues, resulting in inflammation and damage to various organs. A variety of environmental factors, including infections, chemicals or pollutants, and changes in lifestyle, contribute to the increase in autoimmune diseases. Treatment for granulomatosis with polyangiitis, an autoimmune disease, employs immunosuppressive treatments like corticosteroids and cyclophosphamide, which aid in managing inflammation and averting organ damage. Such treatments are therefore fundamental for early intervention and personalized care in managing other autoimmune disorders with similar roots. As evidence, a report by UK’s Office for National Statistics in June 2023 revealed that the global population of people living with multiple sclerosis (MS), another autoimmune disease, rose to 2.9 million in 2023, from 2.8 million in 2022. Consequently, the growing occurrence of autoimmune diseases is fueling the growth of the granulomatosis with polyangiitis treatment market.
How Does The Granulomatosis With Polyangiitis Treatment Market Differ By Segment?
The granulomatosis with polyangiitis treatmentmarket covered in this report is segmented –
1) By Drug Type: Steroids; Immunosuppressant; Other Drug Types
2) By Treatment Type: Immunosuppressants; Corticosteroids
3) By Route Of Administration: Oral; Intravenous
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Steroids: Prednisone; Methylprednisolone; Dexamethasone; Hydrocortisone
2) By Immunosuppressants: Cyclophosphamide; Methotrexate; Azathioprine; Mycophenolate mofetil; Rituximab
3) By Other Drug Types: Plasma Exchange Therapy; Intravenous Immunoglobulin (IVIG); Biologic Agents; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
What New Opportunities Are Emerging From Trends In The Granulomatosis With Polyangiitis Treatment Market?
Companies in the granulomatosis with polyangiitis treatment market are developing advanced products like oral corticosteroids to enhance treatment while minimizing long-term steroid side effects. These medications reduce inflammation and immune activity, commonly used for autoimmune and inflammatory diseases. In October 2024, UK-based AstraZeneca plc received EU approval for Fasenra (bevacizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). The approval is based on favorable results from the MANDARA Phase III trial, which showed that Fasenra achieved remission and reduced reliance on oral corticosteroids.
Who Are The Most Influential Companies In The Granulomatosis With Polyangiitis Treatment Market?
Major companies operating in the granulomatosis with polyangiitis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech Inc., Incyte Corporation, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ChemoCentryx Inc., Medac Pharma Inc., InflaRx GmbH
Access The Complete Report Here:
Which Region Is Leading Innovation In The Granulomatosis With Polyangiitis Treatment Market?
North America was the largest region in the granulomatosis with polyangiitis treatment market in 2024. The regions covered in the granulomatosis with polyangiitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21196&type=smp
Browse Through More Reports Similar to the Global Granulomatosis With Polyangiitis Treatment Market 2025, By The Business Research Company
Fertility Treatments Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/fertility-treatments-global-market-report
Polycystic Ovarian Syndrome Treatment Global Market Report 2025
Alzheimer Disease Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
